期刊
BLOOD
卷 122, 期 16, 页码 2807-2811出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-03-491399
关键词
-
类别
资金
- Ruth and Arnold Fund
- Edward P. Evans foundation
- Celgene Future Leaders in Hematology Award
- Kimberly Patterson Leukemia Fellowship
- National Institutes of Health through Anderson's Cancer Center Support Grant [CA016672]
We sought to describe the clinical features and outcomes of therapy-related chronic myelomonocytic leukemia (t-CMML) and compare with those of de novo CMML. We identified 358 CMML patients, of whom 39 (11%) had t- CMML. Although the groups had similar demographic, hematologic, and molecular alteration profiles, the proportion of patients with intermediate or high CMML-specific cytogenetic risk in the t- CMML was significantly higher than that in the de novo CMML (P = .011). The median latency to develop t-CMML was 6 years. The median overall and leukemia-free survival duration of the t-CMML were shorter than those of the de novo CMML; however, t- CMML itself was not prognostic after adjusting for the effects of other covariates including cytogenetics. These results suggest that compared with de novo CMML, t-CMML is associated with more high-risk cytogenetics that manifest as poor outcomes. We propose that t- CMML be recognized as one of the therapy-related myeloid neoplasms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据